ArticleBone marrow transplantation2005
Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients.
Article in Bone marrow transplantation, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02416206 (A Phase II Trial of High-dose Bendamustine, Etoposide, Cytarabine, and Melphalan), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Trial of High-dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) in the Up-front Treatment of Multiple Myeloma
Who cites it
21 citing papers in PubMed, 50 citations in OpenAlex.
- High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: comparison with younger patients treated on the same protocol.Bone marrow transplantation · 2006Trial
- Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT).American journal of hematology · 2024Article
- Clinical, Laboratory, Cytometry and Cytogenetic Characteristics of a Cohort of Patients Diagnosed with Multiple Myeloma for the First Time in a Third-Level Hospital in Medellín, Colombia, Survival after 8 Years of Follow-Up.International journal of hematology-oncology and stem cell research · 2023Article
- Impact of interval progression before autologous stem cell transplant in patients with multiple myeloma.Frontiers in oncology · 2023Article
- [Multiple myeloma and autologous haematopoietic stem-cell transplantation without cryopreservation: experiences of the Clinical Hematology Department of Casablanca, Morocco].The Pan African medical journal · 2021Article
- Impact of Pre-transplant and Post-transplant Remission Status of Patients on Survival in Newly Diagnosed Multiple Myeloma.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2019Article
- Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma.Blood advances · 2019Article
- Autologous hematopoietic stem-cell transplant in small-sized and peripheral centers: a 10-year experiment.Therapeutic advances in hematology · 2019Article
- High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma.Bone marrow transplantation · 2015Article
- Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Article
- Multiple myeloma in the older adult: better prospects, more challenges.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Review
- Correlation between survival and number of mobilized CD34+ cells in patients with multiple myeloma or Waldenström macroglobulinemia.Pathology oncology research : POR · 2010Article
- BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma.Bone marrow transplantation · 2009Article
- Article
- Outcomes after auto-SCT in African Americans with multiple myeloma.Bone marrow transplantation · 2009Article
- Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols.British journal of haematology · 2009Article
- High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country.Bone marrow transplantation · 2009Article
- Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience.Journal of Korean medical science · 2008Article
- Article
- Autologous stem cell transplantation beyond 60 years of age.Bone marrow transplantation · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autologous stem cell transplantation (ASCT) has an established role in the treatment of symptomatic multiple myeloma (MM). Our aim was to analyse the impact of selected prognostic parameters on the survival of patients with MM after ASCT. The new International Staging System (ISS) was also evaluated. A total of 133 MM patients were transplanted in our centre between 1995 and 2002. Following ASCT, 35% of patients were in complete remission (CR) and 60% were in partial remission (PR). The median progression-free (PFS) and overall (OS) survival from transplantation were 29.5 and 68.8 months, respectively. Transplant-related mortality (TRM) was 3%. On multivariate analysis, factors associated with significantly shorter OS were lack of CR after transplant (P = 0.002, hazard ratio (HR): 3.1), stage 3 according to ISS (P = 0.001, HR: 3.0) and age at transplant over 60 years (P = 0.035, HR: 2.0). The status of disease before ASCT did not significantly affect PFS and OS after transplantation. We conclude that ASCT is a safe and effective procedure in MM patients, associated with low TRM. The survival after ASCT was dependent on response after ASCT, stage according to ISS and age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.